The ROE as of November 2024 (TTM) for Oncternal Therapeutics, Inc. (ONCT) is -177.58%

According to Oncternal Therapeutics, Inc.’s latest financial reports and current stock price. The company's current ROE is -177.58%. This represents a change of 232.03% compared to the average of -53.48% of the last 4 quarters.

Oncternal Therapeutics, Inc. (ONCT) Historical ROE (quarterly & annually)

How has ONCT ROE performed in the past?

The mean historical ROE of Oncternal Therapeutics, Inc. over the last ten years is -170.99%. The current -177.58% ROE has changed 3.86% with respect to the historical average. Over the past ten years (40 quarters), ONCT's ROE was at its highest in in the September 2015 quarter at 808.58%. The ROE was at its lowest in in the December 2015 quarter at -173.91%.

Oncternal Therapeutics, Inc. (ONCT) ROE by Quarter and Year

Discovering the peaks and valleys of Oncternal Therapeutics, Inc. ROE, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.

Oncternal Therapeutics, Inc. (ONCT) Average ROE

How has ONCT ROE performed in the past?

The current ROE of Oncternal Therapeutics, Inc. (ONCT) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages

Oncternal Therapeutics, Inc. (ONCT) ROE vs. Peers

How is ONCT’s ROE compared to its peers?

Oncternal Therapeutics, Inc.’s ROE is less than Neoleukin Therapeutics, Inc. (0%), greater than CytomX Therapeutics, Inc. (-8.54%), greater than Assembly Biosciences, Inc. (-41.34%), greater than Instil Bio, Inc. (-121.46%), greater than Nuvation Bio Inc. (-37.44%), greater than Protara Therapeutics, Inc. (-108.68%), greater than Vaccinex, Inc. (-55.96%), less than Monopar Therapeutics Inc. (1.93%), greater than Miromatrix Medical Inc. (-21731.73%), greater than Surrozen, Inc. (-70.01%), greater than Passage Bio, Inc. (-222.75%), greater than Absci Corporation (-72.53%), greater than Adverum Biotechnologies, Inc. (-46.56%), greater than Kezar Life Sciences, Inc. (-65.14%), greater than Armata Pharmaceuticals, Inc. (-59.73%), less than Pasithea Therapeutics Corp. (89.12%), greater than Aditxt, Inc. (-15595.10%), greater than null (-431.38%),

Build a custom stock screener for Oncternal Therapeutics, Inc. (ONCT) and other stocks

One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Oncternal Therapeutics, Inc. using the financials and key metrics that matter to you in a single view.

The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:

Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.

Get your free trial here.

Oncternal Therapeutics, Inc. (ONCT) and other stocks custom spreadsheet templates

The easiest way to analyze a company like Oncternal Therapeutics, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.

Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.

Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.